Log in to search using one of your social media accounts:

 

European Commission Approves Expanded Use Of Mimpara ® (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis
THOUSAND OAKS, Calif., Aug. 31, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted Marketing Authorization of a pediatric formulation (granules in capsule for opening) of Mimpara® (cinacalcet) for the treatment of secondary hyperparathyroidism (HPT) in children aged three years and older with end‑stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy. "Secondary HPT is a serious and complex condition, and there are currently limited treatment options available for...
Source: Amgen News Release - August 31, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Factors Affecting 4D-CT Accuracy for Hyperparathyroidism Elucidated Factors Affecting 4D-CT Accuracy for Hyperparathyroidism Elucidated
Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 18, 2017 Category: Radiology Tags: Radiology News Source Type: news

The Often Missed Diagnosis of Primary Hyperparathyroidism The Often Missed Diagnosis of Primary Hyperparathyroidism
Dr Arefa Cassoobhoy highlights one of the week's important news stories for primary care.Medscape Internal Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 18, 2017 Category: Consumer Health News Tags: Internal Medicine Commentary Source Type: news

Widespread Underdiagnosis of Hyperparathyroidism in Hypercalcemia Widespread Underdiagnosis of Hyperparathyroidism in Hypercalcemia
Only a minority of patients with hypercalcemia are tested for hyperparathyroidism, and only a minority of those found to have hyperthyroidism receive surgical referrals, according to a new database study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 1, 2017 Category: Surgery Tags: General Surgery News Source Type: news

Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara ® (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis
THOUSAND OAKS, Calif., June 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of a pediatric formulation (granules in capsule for opening) of Mimpara® (cinacalcet). Approval was recommended for the treatment of secondary hyperparathyroidism (HPT) in children aged three years and older with end‑stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy. &quo...
Source: Amgen News Release - June 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Thiazide Treatment in Primary Hyperparathyroidism Thiazide Treatment in Primary Hyperparathyroidism
Thiazides may be a safe and effective treatment alternative for patients with primary hyperparathyroidism when surgery is not an option.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 30, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Parathyroid Biopsy Extent Influences Gamma Probe Findings Parathyroid Biopsy Extent Influences Gamma Probe Findings
During radioguided surgery for hyperparathyroidism, a large proportion of hyperfunctional parathyroid gland must be evaluated to confirm complete excision of abnormal tissue via gamma probe, according to a retrospective review.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 5, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine News Source Type: news

US FDA approves Amgen ’s Parsabiv to treat HPT in adult patients
The US Food and Drug Administration (FDA) has approved Amgen ’s Parsabiv (etelcalcetide) to treat secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 9, 2017 Category: Pharmaceuticals Source Type: news

FDA OKs Novel Calcimimetic for Secondary Hyperparathyroidism FDA OKs Novel Calcimimetic for Secondary Hyperparathyroidism
The drug is the first approved in 12 years to treat secondary hyperparathyroidism in hemodialysis patients, and the first that can be given intravenously by a dialysis team.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 8, 2017 Category: Drugs & Pharmacology Tags: Nephrology News Alert Source Type: news

FDA Approves Amgen's Parsabiv (etelcalcetide) for Secondary Hyperparathyroidism in Adult Patients on Hemodialysis
THOUSAND OAKS, Calif., Feb. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 8, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves Amgen's Parsabiv(TM) (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
THOUSAND OAKS, Calif., Feb. 7, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) ... Biopharmaceuticals, Endocrinology, FDA Amgen, Parsabiv, Etelcalcetide, hyperparathyroid (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 8, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Amgen drug for secondary hyperparathyroidism
(Reuters) - The U.S. Food and Drug Administration has approved Amgen Inc's treatment for secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis, the U.S. biotech company said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - February 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Amgen's Parsabiv ™ (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
Intravenous Administration Puts Delivery in Hands of Healthcare Provider THOUSAND OAKS, Calif., Feb. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Parsabiv is the first therapy approved for this condition in 12 years and the only calcimimetic that can be administered intravenously by the dialysis health care team three times a week at the end of the hemodialysis session. To view ...
Source: Amgen News Release - February 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv(TM) (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis
THOUSAND OAKS, Calif., Jan. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced the Journal of the American Medical Association (JAMA) publication of findings from three Phase 3 studies of Parsabiv™ (etelcalcetide), an inves... Biopharmaceuticals Amgen, Parsabiv, etelcalcetide, hyperparathyroidism (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 11, 2017 Category: Pharmaceuticals Source Type: news

Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv ™ (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis
THOUSAND OAKS, Calif., Jan. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Journal of the American Medical Association (JAMA) publication of findings from three Phase 3 studies of Parsabiv™ (etelcalcetide), an investigational intravenous calcimimetic agent in the U.S. The studies evaluated Parsabiv in more than 1,700 adults with secondary hyperparathyroidism (sHPT) on hemodialysis and showed that the drug produced statistically significant and clinically meaningful reductions in serum parathyroid hormone (PTH) levels, a key marker of sHPT. sHPT is a chronic and serious condition that is often p...
Source: Amgen News Release - January 10, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Calcimimetic Promising for Hyperparathyroidism in ESRD (CME/CE)
(MedPage Today) -- GI adverse events still a problem for patients on hemodialysis (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - January 10, 2017 Category: Urology & Nephrology Source Type: news

Hyperparathyroidism
Title: HyperparathyroidismCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 1/4/2017 12:00:00 AM (Source: MedicineNet Thyroid General)
Source: MedicineNet Thyroid General - January 4, 2017 Category: Endocrinology Source Type: news

Thiazides may be safe choice for hypercalciuria in hyperparathyroidism Thiazides may be safe choice for hypercalciuria in hyperparathyroidism
In nonoperable patients with symptomatic primary hyperparathyroidism (PHPT), thiazides may be used to treat hypercalciuria without significantly exacerbating hypercalcemia, a retrospective study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 3, 2017 Category: Consumer Health News Tags: Urology News Source Type: news

European Commission Approves Parsabiv ™ (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis
First Treatment Advance for Secondary Hyperparathyroidism in More Than a Decade and First Intravenous Calcimimetic to Help Healthcare Providers Lower Key Lab Values THOUSAND OAKS, Calif., Nov. 11, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Parsabiv is the first calcimimetic agent that can be administered intravenously by a healthcare provider three times a week at the en...
Source: Amgen News Release - November 11, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Mayo Clinic PathWays: What's the diagnosis?
  This week's case is that of a 68-year-old woman with a diagnosis of primary hyperparathyroidism. The patient underwent right superior parathyroid gland resection and experienced prolonged paralysis and apnea post-surgery. What was the reason for this result? View the case and make your diagnosis. Learn more about Mayo Clinic PathWays. (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 1, 2016 Category: Databases & Libraries Source Type: news

Amgen Provides Update On Status Of Parsabiv(TM) (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)
THOUSAND OAKS, Calif., Aug. 24, 2016 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv™ (etelcal... Biopharmaceuticals, FDA Amgen, Parsabiv, Etelcalcetide, hyperparathyroid (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 25, 2016 Category: Pharmaceuticals Source Type: news

Amgen Provides Update On Status Of Parsabiv ™ (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)
THOUSAND OAKS, Calif., Aug. 24, 2016 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Amgen is reviewing the Complete Response Letter, and we anticipate a post-action meeting with the FDA later this year to discuss the Complete Response. The Complete Response Letter does not impact our regulatory submissions in other regions. ...
Source: Amgen News Release - August 24, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Elevated PTH With Normal Serum Calcium Level Elevated PTH With Normal Serum Calcium Level
What role do PTH measurements play in the assessment and management of normocalcaemic hyperparathyroidism?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 9, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Managing Normocalcemic Primary HyperparathyroidismManaging Normocalcemic Primary Hyperparathyroidism
Find out about the appropriate management of patients with normocalcemic primary hyperparathyroidism. Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 28, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Rayaldee Approved by FDA for Secondary HyperparathyroidismRayaldee Approved by FDA for Secondary Hyperparathyroidism
The FDA has approved calcifediol (Rayaldee, Opko Health, Inc) for the treatment of adults with secondary hyperparathyroidism associated with vitamin D insufficiency in stage 3 to 4 CKD. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2016 Category: Consumer Health News Tags: Nephrology News Alert Source Type: news

FDA Approves Rayaldee (calcifediol) to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease
MIAMI--(BUSINESS WIRE) June 21, 2016 -- OPKO Health, Inc. (NYSE:OPK) announced that the U.S. Food and Drug Administration (FDA) has approved Rayaldee (calcifediol) extended release capsules for the treatment of secondary hyperparathyroidism (SHPT)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 21, 2016 Category: Drugs & Pharmacology Source Type: news

DiaSorin Webinar Details How to Define and Assess Parathyroid...
The Webinar, hosted by LabRoots, will discuss how the hormone is produced in the body, its role in bone and mineral metabolism, traits of primary and secondary hyperparathyroidism, and patient types...(PRWeb June 02, 2016)Read the full story at http://www.prweb.com/releases/2016/06/prweb13455035.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 2, 2016 Category: Pharmaceuticals Source Type: news

Billionaire's company inks $282 million deal with Swiss firm
Opko Health signed a $282 million deal with Vifor Fresenius Medical Care Renal Pharma (VFMCRP) to commercialize its Rayaldee drug candidate in certain international markets. The Miami-based biotech and pharmaceutical company (NYSE: OPK) led by billionaire Chairman and CEO Dr. Phillip Frost is developing Rayaldee to treat secondary hyperparathyroidism in patients with chronic kidney disease and vitamin D insufficiency. Opko granted Switzerland-based VFMCRP the rights to develop and commercialize… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 9, 2016 Category: Pharmaceuticals Authors: Brian Bandell Source Type: news

Surgery for PHPT improves sleep quality
BALTIMORE – Research into how primary hyperparathyroidism and parathyroidectomy affect sleep quality has been limited, but investigators at the Medical College of Wisconsin, Milwaukee, reported that... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 24, 2016 Category: Endocrinology Source Type: news

Surgery for PHPT improves sleep quality
BALTIMORE – Research into how primary hyperparathyroidism and parathyroidectomy affect sleep quality has been limited, but investigators at the Medical College of Wisconsin, Milwaukee, reported that... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 24, 2016 Category: Neurology Source Type: news

Surgery for PHPT improves sleep quality
BALTIMORE – Research into how primary hyperparathyroidism and parathyroidectomy affect sleep quality has been limited, but investigators at the Medical College of Wisconsin, Milwaukee, reported that... (Source: Family Practice News)
Source: Family Practice News - April 24, 2016 Category: Primary Care Source Type: news

Post-parathyroidectomy follow-up may need to be open-ended
BALTIMORE – Patients who have had parathyroidectomy for primary hyperparathyroidism can have disease recurrence 10 years or longer after surgery, raising the possibility that postop follow-up should... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 23, 2016 Category: Endocrinology Source Type: news

Negative sestamibi scan for primary hyperparathyroidism can mean no referral or surgery
BALTIMORE – In the treatment of primary hyperparathyroidism, clinical guidelines recommend using sestamibi scan for localizing adenoma, but increasingly endocrinologists are using sestamibi results... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 23, 2016 Category: Endocrinology Source Type: news

Surgery Best to Reduce Fractures in HyperparathyroidismSurgery Best to Reduce Fractures in Hyperparathyroidism
Surgically removing the tumor significantly reduces fracture risk over time in primary hyperparathyroidism, whereas bisphosphonate therapy increases fracture risk despite improving bone-mineral density. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 7, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Surgery more effective than drugs for hyperparathyroidism
Stephen FellerLOS ANGELES, April 5 (UPI) -- Treating hyperparathyroidism, a cause of osteoporosis, with bisphosphonate drugs increases risk for bone fracture rather than reducing it, researchers found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 5, 2016 Category: Consumer Health News Source Type: news

For treating a leading cause of osteoporosis, surgery is better than widely used medications
While most cases of osteoporosis are caused by normal aging, another leading cause of the bone-loss disease is a condition called hyperparathyroidism, in which the parathyroid glands release an excessive amount of a hormone that regulates the body’s calcium levels. Doctors commonly treat hyperparathyroidism using a class of prescription drugs called bisphosphonates, including alendronate (marketed under the brand name Fosamax) and ibandronate (Boniva), which are supposed to strengthen bones. Now, a study led by scientists at UCLA found that those drugs actually increase the risk of fracture, meaning that taking them ...
Source: UCLA Newsroom: Health Sciences - April 5, 2016 Category: Universities & Medical Training Source Type: news

To treat a leading cause of osteoporosis, surgery is better than widely used medications
A leading cause of the bone-loss disease osteoporosis is hyperparathyroidism. Doctors commonly treat this using a class of prescription drugs called bisphosphonates, which are supposed to strengthen bones. A new study found those drugs actually increase the risk of fracture, meaning that taking them is worse than doing nothing at all. The research also revealed that patients who have surgery to remove the overactive parathyroid glands have fewer subsequent bone fractures. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 4, 2016 Category: Science Source Type: news

Surgery Beats Medical Treatment in Reducing Fracture Risk in Primary Hyperparathyroidism (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH Parathyroidectomy is associated with reduced fracture risk compared with observation in patients with primary hyperparathyroidism. Bisphosphonate use, meanwhile, is tied to increased risk, according to a retrospective … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 4, 2016 Category: Primary Care Source Type: news

To treat a leading cause of osteoporosis, surgery is better than widely used medications
(University of California - Los Angeles) A leading cause of the bone-loss disease osteoporosis is hyperparathyroidism. Doctors commonly treat this using a class of prescription drugs called bisphosphonates, which are supposed to strengthen bones. A UCLA study found those drugs actually increase the risk of fracture, meaning that taking them is worse than doing nothing at all. The research also revealed that patients who have surgery to remove the overactive parathyroid glands have fewer subsequent bone fractures. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 4, 2016 Category: Global & Universal Source Type: news

Mayo Clinic Q and A: Primary Hyperparathyroidism Typically Doesn’t Cause Early Symptoms
DEAR MAYO CLINIC: After a routine blood test my doctor called and said that I have higher than normal levels of calcium in my blood. He wants me to come back for another appointment to test for something called primary hyperparathyroidism. What causes this condition, and is it treatable? I am 60 and always have [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 1, 2016 Category: Databases & Libraries Source Type: news

Etelcalcetide (calcimimetic) for the Treatment of Secondary Hyperparathyroidism (SHPT)
Etelcalcetide (formerly AMG416), an intravenous injectable calcimimetic agent, is currently under development by Amgen for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on haemodialysis. (Source: Drug Development Technology)
Source: Drug Development Technology - January 18, 2016 Category: Pharmaceuticals Source Type: news

Surgery is more effective than drug in hyperparathyroidism post-kidney transplantation
A new study compared the results of surgery with drug therapy in patients with tertiary hyperparathyroidism, i.e., after a kidney transplant. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 16, 2015 Category: Science Source Type: news

Quantitation of Parathyroid Hormone in Serum or Plasma by Liquid Chromatography-Tandem Mass Spectrometry
Parathyroid hormone (PTH), an 84 amino acid peptide hormone, is an important regulator of calcium homeostasis. Quantitation of PTH in serum is useful for the diagnosis of primary hyperparathyroidism, hypoparathyroidism, and for monitoring osteodystrophy in patients with renal failure. The biological activity of PTH arises from binding of PTH (N terminus) to its target receptor (D’Amour et al., Kidney Int 68: 998–1007, 2005). Several C-terminal and N-terminal fragments circulate in normal subjects. Recent studies have demonstrated that accurate quantitation of PTH fragments may be of clinical value. In this chap...
Source: Springer protocols feed by Imaging/Radiology - November 27, 2015 Category: Radiology Source Type: news

Multiple fractures in a 22-year-old man after a simple fall - Alattas MH, Dimentberg R.
We present the case of a 22-year-old male with longstanding progressive fatigue, weakness and pain around his hips due to an undiagnosed parathyroid adenoma. The resultant primary hyperparathyroidism ultimately caused pathologic fractures. He was admitted ... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - October 11, 2015 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

​Amgen files for FDA approval for drug to treat dialysis patients
Amgen Inc. said it has filed for approval to sell its drug to treat patients with chronic kidney disease on dialysis. Thousand Oaks-based Amgen(Nasdaq: AMGN) said it submitted a new drug application to the U.S. Food and Drug Administration for etelcalcetide, formerly AMG 416, for the treatment of secondary hyperparathyroidism, a condition that can cause fragile bones, bone pain and organ damage. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 26, 2015 Category: American Health Source Type: news

Opko Health stock gains on FDA announcement
Opko Health shares traded up 1.5 percent on Tuesday afternoon after the FDA decided to initiate a review of the company’s Rayaldee drug candidate. The Miami-based biotech and pharmaceutical company (NYSE: OPK), headed by billionaire Chairman and CEO Dr. Phillip Frost, is seeking approval for Rayaldee for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D (CKD) deficiency. Opko submitted an application for the drug based… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 28, 2015 Category: Biotechnology Authors: Brian Bandell Source Type: news

Opko Health stock gains on FDA announcement
Opko Health shares traded up 1.5 percent on Tuesday afternoon after the FDA decided to initiate a review of the company’s Rayaldee drug candidate. The Miami-based biotech and pharmaceutical company (NYSE: OPK), headed by billionaire Chairman and CEO Dr. Phillip Frost, is seeking approval for Rayaldee for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D (CKD) deficiency. Opko submitted an application for the drug based… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - July 28, 2015 Category: Hospital Management Authors: Brian Bandell Source Type: news

Parathyroidectomy Rarely Used in Renal-Transplant PatientsParathyroidectomy Rarely Used in Renal-Transplant Patients
A single-center study finds parathyroidectomy used in only 6.6% of kidney-transplant patients with postsurgical hyperparathyroidism, but when used it provides benefit and doesn't harm the kidney graft. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 3, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Erectile Dysfunction May Resolve With ParathyroidectomyErectile Dysfunction May Resolve With Parathyroidectomy
Pilot data suggest that men with primary hyperparathyroidism who report erectile dysfunction prior to parathyroidectomy may experience improvement in erectile function following surgery. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 21, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news